Literature DB >> 30654049

Anaphylaxis after vaccination reported to the Vaccine Adverse Event Reporting System, 1990-2016.

John R Su1, Pedro L Moro2, Carmen S Ng2, Paige W Lewis2, Maria A Said3, Maria V Cano2.   

Abstract

BACKGROUND: Anaphylaxis, a rare and potentially life-threatening hypersensitivity reaction, can occur after vaccination.
OBJECTIVE: We sought to describe reports of anaphylaxis after vaccination made to the Vaccine Adverse Event Reporting System (VAERS) during 1990-2016.
METHODS: We identified domestic reports of anaphylaxis within VAERS using a combination of Medical Dictionary for Regulatory Activity queries and Preferred Terms. We performed a descriptive analysis, including history of hypersensitivity (anaphylaxis, respiratory allergies, and drug allergies) and vaccines given. We reviewed all serious reports and all nonserious reports with available medical records to determine if they met the Brighton Collaboration case definition for anaphylaxis or received a physician's diagnosis.
RESULTS: During the analytic period, VAERS received 467,960 total reports; 828 met the Brighton Collaboration case definition or received a physician's diagnosis of anaphylaxis: 654 (79%) were classified as serious, and 669 (81%) had medical records available. Of 478 reports in children aged less than 19 years, 65% were male; childhood vaccines were most commonly reported. Of 350 reports in persons aged 19 years or greater, 80% were female, and influenza vaccines were most frequently reported. Overall, 41% of reports described persons with no history of hypersensitivity. We identified 8 deaths, 4 among persons with no history of hypersensitivity.
CONCLUSION: Anaphylaxis after vaccination is rare in the United States and can occur among persons with no history of hypersensitivity. Most persons recover fully with treatment, but serious complications, including death, can occur. Published by Elsevier Inc.

Entities:  

Keywords:  Brighton; Vaccine Adverse Event Reporting System; adverse event; anaphylaxis; epidemiology; hypersensitivity; vaccine

Mesh:

Year:  2019        PMID: 30654049      PMCID: PMC6580415          DOI: 10.1016/j.jaci.2018.12.1003

Source DB:  PubMed          Journal:  J Allergy Clin Immunol        ISSN: 0091-6749            Impact factor:   10.793


  30 in total

1.  Withdrawal of rotavirus vaccine recommendation.

Authors: 
Journal:  MMWR Morb Mortal Wkly Rep       Date:  1999-11-05       Impact factor: 17.586

2.  Intussusception among recipients of rotavirus vaccine--United States, 1998-1999.

Authors: 
Journal:  MMWR Morb Mortal Wkly Rep       Date:  1999-07-16       Impact factor: 17.586

Review 3.  Understanding vaccine safety information from the Vaccine Adverse Event Reporting System.

Authors:  Frederick Varricchio; John Iskander; Frank Destefano; Robert Ball; Robert Pless; M Miles Braun; Robert T Chen
Journal:  Pediatr Infect Dis J       Date:  2004-04       Impact factor: 2.129

4.  How dangerous is food allergy in childhood? The incidence of severe and fatal allergic reactions across the UK and Ireland.

Authors:  C F Macdougall; A J Cant; A F Colver
Journal:  Arch Dis Child       Date:  2002-04       Impact factor: 3.791

5.  Differences in incidence of reported asthma related to age in men and women. A retrospective analysis of the data of the European Respiratory Health Survey.

Authors:  R de Marco; F Locatelli; J Sunyer; P Burney
Journal:  Am J Respir Crit Care Med       Date:  2000-07       Impact factor: 21.405

6.  Emergency department anaphylaxis: A review of 142 patients in a single year.

Authors:  A F Brown; D McKinnon; K Chu
Journal:  J Allergy Clin Immunol       Date:  2001-11       Impact factor: 10.793

7.  Serious adverse events after measles-mumps-rubella vaccination during a fourteen-year prospective follow-up.

Authors:  A Patja; I Davidkin; T Kurki; M J Kallio; M Valle; H Peltola
Journal:  Pediatr Infect Dis J       Date:  2000-12       Impact factor: 2.129

8.  Prevalence of anti-gelatin IgE antibodies in people with anaphylaxis after measles-mumps rubella vaccine in the United States.

Authors:  Vitali Pool; M Miles Braun; John M Kelso; Gina Mootrey; Robert T Chen; John W Yunginger; Robert M Jacobson; Paul M Gargiullo
Journal:  Pediatrics       Date:  2002-12       Impact factor: 7.124

9.  Two case reports of cutaneous adverse reactions following hepatitis B vaccine: lichen planus and granuloma annulare.

Authors:  P R Criado; R de Oliveira Ramos; C Vasconcellos; R F Jardim Criado; N Y S Valente
Journal:  J Eur Acad Dermatol Venereol       Date:  2004-09       Impact factor: 6.166

10.  Risk of anaphylaxis after vaccination of children and adolescents.

Authors:  Kari Bohlke; Robert L Davis; S M Marcy; M M Braun; Frank DeStefano; Steven B Black; John P Mullooly; Robert S Thompson
Journal:  Pediatrics       Date:  2003-10       Impact factor: 7.124

View more
  21 in total

Review 1.  Fatal Anaphylaxis: Epidemiology and Risk Factors.

Authors:  Irene Mikhail; David R Stukus; Benjamin T Prince
Journal:  Curr Allergy Asthma Rep       Date:  2021-04-07       Impact factor: 4.806

2.  Safety surveillance of meningococcal group B vaccine (Bexsero®), Vaccine Adverse Event Reporting System, 2015-2018.

Authors:  Silvia Perez-Vilar; Graça M Dores; Paige L Marquez; Carmen S Ng; Maria V Cano; Anuja Rastogi; Lucia Lee; John R Su; Jonathan Duffy
Journal:  Vaccine       Date:  2021-12-07       Impact factor: 3.641

3.  COVID-19 vaccination, do women suffer from more side effects than men? A retrospective cross-sectional study.

Authors:  Harith Kh Al-Qazaz; Luma M Al-Obaidy; Heba M Attash
Journal:  Pharm Pract (Granada)       Date:  2022-06-10

4.  Vaccine-Associated Anaphylaxis.

Authors:  Michael M McNeil
Journal:  Curr Treat Options Allergy       Date:  2019-07-16

5.  Safety Surveillance of Bivalent Meningococcal Group B Vaccine, Vaccine Adverse Event Reporting System, 2014-2018.

Authors:  Jonathan Duffy; Paige Marquez; Graça M Dores; Carmen Ng; John Su; Maria Cano; Silvia Perez-Vilar
Journal:  Open Forum Infect Dis       Date:  2020-10-27       Impact factor: 3.835

6.  Allergy to Polyethilenglicole of Anti-SARS CoV2 Vaccine Recipient: A Case Report of Young Adult Recipient and the Management of Future Exposure to SARS-CoV2.

Authors:  Vincenzo Restivo; Giuseppina Candore; Maria Barrale; Ester Caravello; Giorgio Graziano; Rosa Onida; Maurizio Raineri; Salvatore Tiralongo; Ignazio Brusca
Journal:  Vaccines (Basel)       Date:  2021-04-21

Review 7.  The Risk of Allergic Reaction to SARS-CoV-2 Vaccines and Recommended Evaluation and Management: A Systematic Review, Meta-analysis, GRADE Assessment, and International Consensus Approach.

Authors:  Matthew Greenhawt; Elissa M Abrams; Marcus Shaker; Derek K Chu; David Kahn; Cem Akin; Waleed Alqurashi; Peter Arkwright; James L Baldwin; Moshe Ben-Shoshan; Jonathan Bernstein; Theresa Bingeman; Katerina Blumchen; Aideen Byrne; Antonio Bognanni; Dianne Campbell; Ronna Campbell; Zain Chagla; Edmond S Chan; Jeffrey Chan; Pasquale Comberiatti; Timothy E Dribin; Anne K Ellis; David M Fleischer; Adam Fox; Pamela A Frischmeyer-Guerrerio; Remi Gagnon; Mitchell H Grayson; Caroline C Horner; Johnathan Hourihane; Constance H Katelaris; Harold Kim; John M Kelso; David Lang; Dennis Ledford; Michael Levin; Jay Lieberman; Richard Loh; Doug Mack; Bruce Mazer; Gissele Mosnaim; Daniel Munblit; S Shahzad Mustafa; Anil Nanda; John Oppenheimer; Kirsten P Perrett; Allison Ramsey; Matt Rank; Kara Robertson; Javed Shiek; Jonathan M Spergel; David Stukus; Mimi Lk Tang; James M Tracy; Paul J Turner; Anna Whalen-Browne; Dana Wallace; Julie Wang; Susan Wasserman; John K Witty; Margitta Worm; Timothy K Vander Leek; David Bk Golden
Journal:  J Allergy Clin Immunol Pract       Date:  2021-06-18

8.  Pfizer-BioNTech COVID-19 Vaccine Tolerance in Allergic versus Non-Allergic Individuals.

Authors:  Marita Nittner-Marszalska; Marta Rosiek-Biegus; Agnieszka Kopeć; Robert Pawłowicz; Magdalena Kosińska; Aleksandra Łata; Leszek Szenborn
Journal:  Vaccines (Basel)       Date:  2021-05-25

Review 9.  Review: Vaccine Myth-Buster - Cleaning Up With Prejudices and Dangerous Misinformation.

Authors:  Paul Löffler
Journal:  Front Immunol       Date:  2021-06-10       Impact factor: 7.561

10.  Polyethylene glycol (PEG) is a cause of anaphylaxis to the Pfizer/BioNTech mRNA COVID-19 vaccine.

Authors:  Priya Sellaturay; Shuaib Nasser; Sabita Islam; Padmalal Gurugama; Pamela W Ewan
Journal:  Clin Exp Allergy       Date:  2021-04-09       Impact factor: 5.018

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.